Anne H. Thomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne H. Thomson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Michael Harris
2 shared publicationsAnthony Harnden
Department of Primary Health Care, University of Oxford, Headington, Oxford, UK
1 shared publicationC Wallis
Great Ormond Street Hospital, London, UK
1 shared publicationH. J. Bunn
Department of Respiratory Paediatrics, John Radcliffe Hospital, Headley Way, Headington, Oxford, United Kingdom OX3 9DU
1 shared publicationI M Balfour Lynn
Royal Brompton and Harefield NHS Trust, London, UK
1 shared publicationJ Hull
John Radcliffe Hospital, Oxford, UK
1 shared publication
Latest Publications
- Open Access
Community-acquired pneumonia in children: what's new?
The community-acquired pneumonia in children guidelines have just been updated with new evidence on incidence, aetiology and management. This guidance should improve patient care.
Open AccessCommunity-acquired pneumonia in children: what's new?
The community-acquired pneumonia in children guidelines have just been updated with new evidence on incidence, aetiology and management. This guidance should improve patient care.
- Top Cited PapersOpen Access
British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011
The British Thoracic Society first published management guidelines for community acquired pneumonia in children in 2002 and covered available evidence to early 2000. These updated guidelines represent a review of new evidence since then and consensus clinical opinion where evidence was not found. This document incorporates material from the 2002 guidelines and supersedes the previous guideline document.
Top Cited PapersOpen AccessBritish Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011
The British Thoracic Society first published management guidelines for community acquired pneumonia in children in 2002 and covered available evidence to early 2000. These updated guidelines represent a review of new evidence since then and consensus clinical opinion where evidence was not found. This document incorporates material from the 2002 guidelines and supersedes the previous guideline document.
- Open Access
- 15 July 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (1_suppl) , 23-28
Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis
- 15 July 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (1_suppl) , 23-28
Open AccessPalivizumab, pneumococcal and influenza vaccination in cystic fibrosis
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 1 (3) , 331-3
Antibiotics for community-acquired pneumonia in children: is intravenous delivery necessary?
Evaluation of: Atkinson M, Lakhanpaul M, Smyth A et al. A multicentre randomised controlled equivalence trial comparing oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children PIVOT Trial. Thorax DOI: 10.1136/thx.2006.074906 (2007) (Epub ahead of print). Children with radiologically confirmed community-acquired pneumonia are frequently admitted to hospital and treated with parenteral antibiotics, yet oral antibiotics are well absorbed and are effective against the main bacterial agent, Streptococcus pneumoniae. The current randomized study evaluates for equivalence of oral versus intravenous antibiotics in previously healthy children admitted to hospital with moderate/severe pneumonia. Oral antibiotic treatment was found to be equivalent and associated with a shorter duration of hospital stay.
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 1 (3) , 331-3
Antibiotics for community-acquired pneumonia in children: is intravenous delivery necessary?
Evaluation of: Atkinson M, Lakhanpaul M, Smyth A et al. A multicentre randomised controlled equivalence trial comparing oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children PIVOT Trial. Thorax DOI: 10.1136/thx.2006.074906 (2007) (Epub ahead of print). Children with radiologically confirmed community-acquired pneumonia are frequently admitted to hospital and treated with parenteral antibiotics, yet oral antibiotics are well absorbed and are effective against the main bacterial agent, Streptococcus pneumoniae. The current randomized study evaluates for equivalence of oral versus intravenous antibiotics in previously healthy children admitted to hospital with moderate/severe pneumonia. Oral antibiotic treatment was found to be equivalent and associated with a shorter duration of hospital stay.
- 1 January 2007
- Published by Springer Nature in Pediatric Drugs
- Vol. 9 (6) , 401-411
Management of Community-Acquired Pneumonia in Children
Community-acquired pneumonia (CAP) is a significant cause of childhood morbidity and mortality worldwide. Viral etiology is most common in young children and decreases with age. Streptococcus pneumoniae is the single most common bacterial cause across all age groups. Atypical organisms present similarly across all age groups and may be more common than previously recognized. A bacterial pneumonia should be considered in children presenting with fever >38.5°C, tachypnea, and chest recession. Oxygen therapy is life saving and should be given when oxygen saturation is S. pneumoniae prevalence rates are increasing and have been linked to community antibacterial prescribing. Most pneumococci remain sensitive to high-dose penicillin-based antibacterials but macrolide resistance is also a problem in some communities. However, primary combination treatment with macrolides is indicated in areas where there is a high prevalence of atypical organisms. The most common complications in CAP are parapneumonic effusions and empyema. The use of ultrasonography combined with intercostal drainage augmented with the use of fibrinolytic therapy has significantly reduced the morbidity associated with these complications. There is increasing evidence that a preventative strategy with the 7-valent pneumococcal conjugate vaccine (PCV-7) results in a significant fall in CAP in early childhood.
- 1 January 2007
- Published by Springer Nature in Pediatric Drugs
- Vol. 9 (6) , 401-411
Management of Community-Acquired Pneumonia in Children
Community-acquired pneumonia (CAP) is a significant cause of childhood morbidity and mortality worldwide. Viral etiology is most common in young children and decreases with age. Streptococcus pneumoniae is the single most common bacterial cause across all age groups. Atypical organisms present similarly across all age groups and may be more common than previously recognized. A bacterial pneumonia should be considered in children presenting with fever >38.5°C, tachypnea, and chest recession. Oxygen therapy is life saving and should be given when oxygen saturation is S. pneumoniae prevalence rates are increasing and have been linked to community antibacterial prescribing. Most pneumococci remain sensitive to high-dose penicillin-based antibacterials but macrolide resistance is also a problem in some communities. However, primary combination treatment with macrolides is indicated in areas where there is a high prevalence of atypical organisms. The most common complications in CAP are parapneumonic effusions and empyema. The use of ultrasonography combined with intercostal drainage augmented with the use of fibrinolytic therapy has significantly reduced the morbidity associated with these complications. There is increasing evidence that a preventative strategy with the 7-valent pneumococcal conjugate vaccine (PCV-7) results in a significant fall in CAP in early childhood.
- Open Access
- 24 May 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 91 (2) , 188-191
Obesity and the pulmonologist
Obese children have more respiratory symptoms than their normal weight peers and respiratory related pathology increases with increasing weight. Some will need specialist assessment (box 1). Obesity produces mechanical effects on respiratory system performance. Breathlessness, wheeze, and cough are not related to increased airway responsiveness and may respond more to weight loss than bronchodilator therapy. A significant number of obese children have signs and symptoms of obstructive sleep apnoea largely related to the effect of obesity on upper airway dimensions. It seems likely that unless action is taken soon,34 increasing numbers of children will experience preventable respiratory morbidity as a result of nutritional obesity.
- 24 May 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 91 (2) , 188-191
Open AccessObesity and the pulmonologist
Obese children have more respiratory symptoms than their normal weight peers and respiratory related pathology increases with increasing weight. Some will need specialist assessment (box 1). Obesity produces mechanical effects on respiratory system performance. Breathlessness, wheeze, and cough are not related to increased airway responsiveness and may respond more to weight loss than bronchodilator therapy. A significant number of obese children have signs and symptoms of obstructive sleep apnoea largely related to the effect of obesity on upper airway dimensions. It seems likely that unless action is taken soon,34 increasing numbers of children will experience preventable respiratory morbidity as a result of nutritional obesity.
- 1 February 2005
- Published by Wiley in Pediatric Pulmonology
- Vol. 39 (2) , 127-134
Medical management of parapneumonic pleural disease
Considerable heterogeneity exists in the management of parapneumonic pleural disease. A randomized controlled trial (RCT) demonstrated the effectiveness of small‐catheter drainage with fibrinolysis, but surgical devotees suggest this may only be applicable to “early” cases. We examined evidence‐based medical management in “all‐comers.” We performed a retrospective database analysis of the management of all children with complex pleural effusion admitted to the John Radcliffe Hospital over the 7‐year period 1996–2003. One hundred and ten children were admitted. Ten were excluded as they were part of a multicenter RCT and had received intrapleural saline instead of urokinase. Of the remaining 100, 51 were female and 49 male. Median age on admission was 5.8 years (range, 0.3–16.5). Symptoms preadmission averaged 11 days, with December the most common month for presentation. Ninety‐six underwent chest ultrasound, confirming an effusion in all, described as loculated/septated (68) or echogenic (11). In 17 cases, no specific comment was made regarding the nature of the fluid seen on ultrasound. Ninety‐five had subsequent chest tube drainage and then received intrapleural fibrinolysis with urokinase. An etiological organism was identified in 21 cases (21%) (Streptococcus pneumoniae in 10, group A Streptococcus in 5, Staphylococcus aureus in 4, Haemophilus influenzae in 1, and coliform in 1). In a further 9 cases (9%), Gram‐positive organisms were seen on pleural fluid microscopy, but did not grow on culture. Two (2%) required surgery due to the persistence of symptoms and an inadequate response to medical management. Median duration of admission was 7 days (range, 2–21 days); median duration of stay from intervention was 5 days (range, 2–19 days). At median follow‐up of 8 weeks (range, 3–20 weeks), all children were symptom‐free, with minimal pleural thickening on chest X‐ray. In conclusion, antibiotic therapy with chest drain insertion and intrapleural urokinase is effective in treating complex parapneumonic effusion and is associated with a good long‐term outcome.
- 1 February 2005
- Published by Wiley in Pediatric Pulmonology
- Vol. 39 (2) , 127-134
Medical management of parapneumonic pleural disease
Considerable heterogeneity exists in the management of parapneumonic pleural disease. A randomized controlled trial (RCT) demonstrated the effectiveness of small‐catheter drainage with fibrinolysis, but surgical devotees suggest this may only be applicable to “early” cases. We examined evidence‐based medical management in “all‐comers.” We performed a retrospective database analysis of the management of all children with complex pleural effusion admitted to the John Radcliffe Hospital over the 7‐year period 1996–2003. One hundred and ten children were admitted. Ten were excluded as they were part of a multicenter RCT and had received intrapleural saline instead of urokinase. Of the remaining 100, 51 were female and 49 male. Median age on admission was 5.8 years (range, 0.3–16.5). Symptoms preadmission averaged 11 days, with December the most common month for presentation. Ninety‐six underwent chest ultrasound, confirming an effusion in all, described as loculated/septated (68) or echogenic (11). In 17 cases, no specific comment was made regarding the nature of the fluid seen on ultrasound. Ninety‐five had subsequent chest tube drainage and then received intrapleural fibrinolysis with urokinase. An etiological organism was identified in 21 cases (21%) (Streptococcus pneumoniae in 10, group A Streptococcus in 5, Staphylococcus aureus in 4, Haemophilus influenzae in 1, and coliform in 1). In a further 9 cases (9%), Gram‐positive organisms were seen on pleural fluid microscopy, but did not grow on culture. Two (2%) required surgery due to the persistence of symptoms and an inadequate response to medical management. Median duration of admission was 7 days (range, 2–21 days); median duration of stay from intervention was 5 days (range, 2–19 days). At median follow‐up of 8 weeks (range, 3–20 weeks), all children were symptom‐free, with minimal pleural thickening on chest X‐ray. In conclusion, antibiotic therapy with chest drain insertion and intrapleural urokinase is effective in treating complex parapneumonic effusion and is associated with a good long‐term outcome.
- 2 April 2004
- Published by Springer Nature in Pediatric Cardiology
- Vol. 25 (4) , 557-559
Noninvasive Ventilation for the Management of Pulmonary Hypertension Associated with Congenital Heart Disease in Children
The use of noninvasive ventilation to support children with secondary pulmonary hypertension has not previously been reported. We present four children with secondary pulmonary hypertension in association with complex congenital and acquired cardiorespiratory anomalies who have been successfully managed in hospital and then discharged into the community on noninvasive ventilation, thus placing them in environments more suited for growth and development.
- 2 April 2004
- Published by Springer Nature in Pediatric Cardiology
- Vol. 25 (4) , 557-559
Noninvasive Ventilation for the Management of Pulmonary Hypertension Associated with Congenital Heart Disease in Children
The use of noninvasive ventilation to support children with secondary pulmonary hypertension has not previously been reported. We present four children with secondary pulmonary hypertension in association with complex congenital and acquired cardiorespiratory anomalies who have been successfully managed in hospital and then discharged into the community on noninvasive ventilation, thus placing them in environments more suited for growth and development.
- Open Access
Randomised trial of intrapleural urokinase in the treatment of childhood empyema
Background: The role of intrapleural fibrinolytic agents in the treatment of childhood empyema has not been established. A randomised double blind placebo controlled trial of intrapleural urokinase was performed in children with parapneumonic empyema. Methods: Sixty children (median age 3.3 years) were recruited from 10 centres and randomised to receive either intrapleural urokinase 40 000 units in 40 ml or saline 12 hourly for 3 days. The primary outcome measure was length of hospital stay after entry to the trial. Results: Treatment with urokinase resulted in a significantly shorter hospital stay (7.4 v 9.5 days; ratio of geometric means 1.28, CI 1.16 to 1.41 p=0.027). A post hoc analysis showed that the use of small percutaneous drains was also associated with shorter hospital stay. Children treated with a combination of urokinase and a small drain had the shortest stay (6.0 days, CI 4.6 to 7.8). Conclusion: Intrapleural urokinase is effective in treating empyema in children and significantly shortens hospital stay.
Open AccessRandomised trial of intrapleural urokinase in the treatment of childhood empyema
Background: The role of intrapleural fibrinolytic agents in the treatment of childhood empyema has not been established. A randomised double blind placebo controlled trial of intrapleural urokinase was performed in children with parapneumonic empyema. Methods: Sixty children (median age 3.3 years) were recruited from 10 centres and randomised to receive either intrapleural urokinase 40 000 units in 40 ml or saline 12 hourly for 3 days. The primary outcome measure was length of hospital stay after entry to the trial. Results: Treatment with urokinase resulted in a significantly shorter hospital stay (7.4 v 9.5 days; ratio of geometric means 1.28, CI 1.16 to 1.41 p=0.027). A post hoc analysis showed that the use of small percutaneous drains was also associated with shorter hospital stay. Children treated with a combination of urokinase and a small drain had the shortest stay (6.0 days, CI 4.6 to 7.8). Conclusion: Intrapleural urokinase is effective in treating empyema in children and significantly shortens hospital stay.